Autologous Fat Grafting Clinical Trial
Official title:
The Volumetric Analysis of Fat Grafting for Aesthetic Body Contouring
NCT number | NCT03544593 |
Other study ID # | 11-01-2017 |
Secondary ID | |
Status | Recruiting |
Phase | N/A |
First received | |
Last updated | |
Start date | January 4, 2018 |
Est. completion date | March 2019 |
Title: The Volumetric Analysis of Fat Grafting for Aesthetic Body Contouring.
Subjects who wish to undergo fat grafting for aesthetic body contouring will be offered
enrollment to the study. The study will consist of a Screening/Baseline visit, Surgery day
and 3 follow up visits. Each follow up visit will utilize Vectra 3D photography (Canfeild,
NJ) to collect volumetric data. At the conclusion of the study, Volume data from Baseline and
3 follow up visits will be analyzed to determine fat retention rates.
Status | Recruiting |
Enrollment | 50 |
Est. completion date | March 2019 |
Est. primary completion date | March 2019 |
Accepts healthy volunteers | Accepts Healthy Volunteers |
Gender | All |
Age group | 18 Years to 65 Years |
Eligibility |
Inclusion Criteria: 1. Females or Males in good general health age 18 - 65 years of age 2. Must be willing to give and sign a HIPAA form and informed consent form 3. Must be willing and able to comply with all study protocols and schedules 4. Negative urine pregnancy test prior to surgery treatment (if applicable) 5. The patient must have had a stable weight (no fluctuation of >15 pounds in a year), diet, and physical activity for the previous 6 months Exclusion Criteria: 1. Pregnancy, currently breast feeding or planning pregnancy for the duration of the trial 2. History of breast cancer if fat grafting to breasts 3. Patients who smoke or use nicotine products 4. Any UNCONTROLLED systemic disease -a potential patient in whom therapy for a systemic disease is not yet stabilized will not be considered for entry into the study 5. Diabetes Mellitus 6. Subject has a clinically significant coagulation disorder or disease, defined as a platelet count < 100,000 per microliter or International Normalized Ratio > 1.5 within 4 weeks of surgery 7. Patients under the age of 18 8. Patients undergoing fat grafting but refuse enrollment 9. Patients with an active infection 10. Current participation or participation within 30 days prior to the start of this study in a drug or other investigational research study. |
Country | Name | City | State |
---|---|---|---|
United States | Kelly Costin | Huntersville | North Carolina |
Lead Sponsor | Collaborator |
---|---|
Hunstad Kortesis Bharti Cosmetic Sugrery | Allergan |
United States,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Graft retention | Vectra 3D volumetric analysis will be utilized to evaluate graft retention. | 9 months | |
Secondary | Volume of adipose harvested (mL) | Intra Op | ||
Secondary | Volume of adipocyte injected (mL) | Intra Op | ||
Secondary | Operating room time (harvesting, processing, and reinjection time) (min) | Intra Op | ||
Secondary | Standardized before and after photos | Pre op, 3 months, 6 months, 9 months |
Status | Clinical Trial | Phase | |
---|---|---|---|
Withdrawn |
NCT01750424 -
3-D Imaging Assessment of Scar Formation and Would Healing in Fat Grafted vs Non-Fat Grafted Facial Reconstruction Wound Sites
|
Phase 1/Phase 2 | |
Terminated |
NCT04906811 -
Prospective Comparison of Revolve™ and AuraGen 123 With AuraClens™ in Autologous Fat Grafting to the Breast
|
N/A | |
Not yet recruiting |
NCT06343831 -
Quantitative Assessment of Autologous Fat Transfer
|
N/A |